The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Glucagon was the last receptor most pharmacologists would have chosen as a partner for GLP-1 in treating metabolic disease. Survodutide's development is the story of why they were wrong.
The standard understanding of glucagon in metabolic biology: glucagon is an alpha-cell pancreatic hormone whose primary physiological role is counter-regulation of insulin. When blood glucose falls, glucagon rises — triggering hepatic glycogenolysis and gluconeogenesis to restore euglycemia. In type 2 diabetes, glucagon is paradoxically elevated and contributes to fasting hyperglycemia. The logical therapeutic response — in a metabolic disease context — would be to suppress glucagon, not activate its receptor. GLP-1 agonists partly work through glucagon suppression. The history of glucagon receptor agonism in metabolic disease is therefore a history of avoidance.
The insight that changed this: glucagon receptor activation has profoundly different effects in the liver than in the pancreas. In hepatocytes, GCGR activation: drives fatty acid beta-oxidation in mitochondria — burning hepatic fat for energy; suppresses lipogenesis — reducing new fat synthesis; stimulates FGF21 production — a hepatokine with beneficial metabolic effects on adipose tissue and energy expenditure; promotes thermogenesis via uncoupled mitochondrial respiration. These hepatic effects are entirely absent from pure GLP-1 receptor agonism. In MASH — where the liver is the primary disease organ, accumulating fat that drives inflammation, fibrosis, and eventually cirrhosis — direct hepatic fat-oxidizing effects from the glucagon receptor could plausibly produce superior outcomes to GLP-1 alone.
The critical barrier to glucagon receptor monotherapy: glucagon raises blood glucose through both glycogenolysis and gluconeogenesis. A pure glucagon receptor agonist would cause hyperglycemia — precisely the opposite of what is needed in metabolic disease. The dual GLP-1/GCGR agonist approach solves this pharmacologically: GLP-1 receptor activation stimulates glucose-dependent insulin secretion and suppresses glucose-dependent glucagon — directly neutralizing the glycemic liability of glucagon receptor co-agonism. The two components are designed to counterbalance each other metabolically while their combined beneficial effects are additive on weight, energy expenditure, and hepatic fat.
THE CENTRAL TENSION
Survodutide is Boehringer Ingelheim's bet that the glucagon receptor — not the GIP receptor — is the right second partner for GLP-1 in treating metabolic liver disease. Tirzepatide went GLP-1 + GIP and produced the highest approved weight loss efficacy. Survodutide went GLP-1 + glucagon and produced striking MASH resolution in Phase 2 (62% vs 14% placebo). The two dual-agonist strategies are not competing head-to-head — they are targeting different dimensions of the same metabolic disease cluster. GLP-1 + GIP: superior pure weight loss. GLP-1 + glucagon: potentially superior liver disease resolution through direct hepatic fat oxidation. For the enormous population of people with both obesity and MASH — estimated at hundreds of millions worldwide — the question of which dual mechanism produces better liver outcomes is one of the most important unanswered questions in metabolic pharmacology. Phase 3 LIVERAGE (MASH) will answer it.
MASH (Metabolic Dysfunction-Associated Steatohepatitis) is the fastest-growing liver disease globally. It is the compound's primary indication and the reason the FDA granted Breakthrough Therapy status. Understanding MASH is essential for understanding survodutide's significance.
MASH is the progressive inflammatory form of metabolic-dysfunction associated steatotic liver disease (MASLD) — previously called NASH/NAFLD. Estimated to affect 20-30% of the global population in the steatotic form (MASLD); 3-5% have the inflammatory MASH form. MASH leads to fibrosis progression, cirrhosis, liver failure, hepatocellular carcinoma, and is now the leading indication for liver transplantation in the US. Until resmetirom (Rezdiffra, FDA-approved March 2024 as the first dedicated MASH drug), there were no approved MASH-specific pharmacotherapies — a major clinical unmet need. Survodutide is being positioned as the second approved MASH therapy and potentially the first with both weight management and direct hepatic anti-steatotic action.
The importance of fibrosis staging in MASH: MASH fibrosis progresses from F0 (no fibrosis) through F4 (cirrhosis). The LIVERAGE trial targets F2-F3 (moderate to advanced fibrosis) — the most clinically important stages where intervention before cirrhosis can prevent irreversible liver damage. LIVERAGE-Cirrhosis addresses F4 — compensated cirrhosis where treatment options are extremely limited. The FDA Breakthrough Therapy designation applies to non-cirrhotic MASH with F2-F3 fibrosis — exactly where preventing progression to cirrhosis is most achievable and most impactful.
Survodutide's GLP-1R component mirrors semaglutide's mechanism: appetite suppression via hypothalamic and brainstem GLP-1 receptors; glucose-dependent insulin secretion from pancreatic beta cells; gastric emptying delay; glucagon suppression (glucose-dependent). This component drives the bulk of the weight loss observed in Phase 2 and Phase 3 obesity trials — the GLP-1 mechanism is well-characterised from the semaglutide and tirzepatide programs. The GLP-1 component also manages the hyperglycemic risk from the glucagon component: by stimulating glucose-dependent insulin secretion and suppressing glucagon in a glucose-dependent manner, the GLP-1 receptor action counterbalances GCGR-driven glycogenolysis and gluconeogenesis. This is the pharmacological elegance of the dual approach.
Survodutide's GCGR component is the pharmacological innovation that distinguishes it from every approved GLP-1 agonist. Glucagon receptors are expressed on hepatocytes at high density — the liver is the primary glucagon target organ. GCGR activation on hepatocytes produces: (1) Hepatic fat oxidation — activates hormone-sensitive lipase and peroxisomal/mitochondrial beta-oxidation pathways; mobilises triglycerides from lipid droplets; this is the direct anti-steatotic mechanism that makes survodutide particularly effective for MASH. (2) FGF21 induction — glucagon receptor signalling in hepatocytes induces fibroblast growth factor 21 (FGF21) production; FGF21 acts on adipose tissue and brain to improve insulin sensitivity, increase energy expenditure, and reduce triglycerides. (3) Thermogenesis — glucagon increases resting energy expenditure by 5-15% via sympathetic nervous system activation and mitochondrial uncoupling in brown adipose tissue; this thermogenic effect is the mechanism behind the comparable weight loss between survodutide and tirzepatide despite different receptor profiles — the GIP receptor in tirzepatide drives some thermogenesis, and the GCGR in survodutide drives it via a different pathway. (4) Suppression of hepatic lipogenesis — GCGR activation reduces SREBP-1c-driven de novo lipogenesis in the liver.
The MASH pathophysiology: hepatic fat accumulates from multiple sources — dietary fat delivery via chylomicrons, de novo lipogenesis from excess carbohydrate, and adipose tissue lipolysis releasing free fatty acids. The fat accumulation triggers oxidative stress, lipotoxicity, hepatic inflammation, and eventually fibrosis. GLP-1 receptor agonism alone reduces MASH via weight loss and some insulin sensitisation, but has no direct hepatic fat-burning mechanism. The NEJM semaglutide NASH trial showed MASH resolution in 59% vs 17% placebo — impressive, but mediated primarily through weight loss. Survodutide adds direct hepatic fat oxidation through GCGR — potentially addressing liver fat through both weight-loss-mediated and weight-loss-independent pathways simultaneously. The Phase 2 NEJM comparison (62% resolution vs 47-43% at other doses vs 14% placebo) supports this theoretical advantage.
Survodutide has among the most current and most impressive clinical evidence of any pipeline compound in this book. The Phase 2 MASH data in the NEJM and the Phase 3 SYNCHRONIZE-1 results from April 2026 are both landmark publications.
Le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial. Lancet Diabetes and Endocrinology. 2024;12(3):162-173. PMID 38330987. Design: randomised Phase 2b; n=not specified in published abstract; doses 0.3-4.8mg weekly; 46 weeks. Survodutide 4.8mg: -18.7% mean weight loss; 40% of participants achieved ≥20% weight loss. All doses outperformed placebo significantly. The 18.7% Phase 2 figure compares favourably with semaglutide's Phase 3 -14.9% (STEP 1) — though Phase 2 vs Phase 3 comparisons across different populations are imprecise. The Phase 3 SYNCHRONIZE-1 result (-16.6% at 76 weeks) represents the most appropriate comparator to approved drugs.
Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine. Published July 25, 2024. doi:10.1056/NEJMoa2401755. Design: 48-week, randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial. Population: n=293 adults with biopsy-confirmed MASH and liver fibrosis (stages F1-F3). Doses: survodutide 2.4mg, 4.8mg, and 6.0mg vs placebo — all weekly subcutaneous injection. PRIMARY ENDPOINT — MASH resolution without fibrosis worsening: 2.4mg = 47%; 4.8mg = 62%; 6.0mg = 43%; placebo = 14% (p<0.001 for dose-response). SECONDARY ENDPOINTS: ≥30% liver fat reduction (MRI-PDFF): 63% (2.4mg), 67% (4.8mg), 57% (6.0mg) vs 14% placebo. Fibrosis improvement ≥1 stage: 34%, 36%, 34% vs 22% placebo. The dose-response pattern shows 4.8mg as the optimal dose — the U-shaped response where 6.0mg performs less well than 4.8mg is a common finding in GLP-1 class compounds where higher GI burden at the highest doses leads to more discontinuations. This paper is the primary basis for FDA Breakthrough Therapy designation.
SAFETY: Adverse events more frequent with survodutide vs placebo: nausea 66% vs 23%; diarrhea 49% vs 23%; vomiting 41% vs 4%. Serious adverse events: 8% vs 7% (not significantly different). The GI adverse event profile is consistent with the GLP-1 class — concentrated at dose escalation, manageable with appropriate titration. The high nausea rate (66%) versus semaglutide historical rates (~44%) may reflect the higher relative glucagon receptor activity in survodutide driving additional GI effects.
Boehringer Ingelheim press release, April 29, 2026. SYNCHRONIZE-1 Phase 3 trial topline results. Design: global Phase 3; obesity or overweight without T2D; 76 weeks; survodutide 3.6mg or 6.0mg weekly vs placebo. Co-primary endpoints: percent change in body weight (efficacy estimand) and percent change in body weight (treatment-regimen estimand). RESULTS: Survodutide achieved -16.6% mean weight loss at 76 weeks (efficacy estimand) vs -3.2% placebo (p<0.0001). Mean absolute weight loss: 17.8 kg (39.2 lb). Both co-primary endpoints met. Key secondary endpoint (waist circumference reduction) also met. Full data to be presented at ADA Scientific Sessions June 2026. The -16.6% Phase 3 result positions survodutide above semaglutide (-14.9% STEP 1) and comparable to tirzepatide (-22.5% SURMOUNT-1 at highest dose) — though the maximum dose and population are not directly comparable across trials.
LIVERAGE Phase 3: initiated October 2024 following FDA Breakthrough Therapy designation. Two components: (1) LIVERAGE — adults with MASH and moderate-to-advanced fibrosis (stages 2-3), non-cirrhotic; 52-week primary endpoint (MASH histology improvement) + 7-year long-term extension (end-stage liver disease outcomes). (2) LIVERAGE-Cirrhosis — compensated MASH cirrhosis (fibrosis stage 4); extended monitoring. These are the most ambitious MASH trials ever designed — the 7-year outcomes arm will establish whether survodutide prevents end-stage liver disease, liver transplantation, and liver-related death. Results from LIVERAGE Phase 3 are anticipated 2027-2028.
Trial
Indication
Design
Key Result
Grade
Phase 2 obesity (Lancet DE 2024)
Obesity without T2D
DBRCT; Phase 2b; 46 weeks
-18.7% WL at 4.8mg; 40% achieved ≥20% WL
B
Phase 2 MASH (NEJM 2024)
MASH + fibrosis F1-F3
DBRCT; Phase 2; 48 weeks; n=293
62% MASH resolution (4.8mg) vs 14% placebo; 67% ≥30% liver fat reduction
B
SYNCHRONIZE-1 Phase 3 (April 2026)
Obesity without T2D
Phase 3; 76 weeks; topline
−16.6% WL vs −3.2% placebo; both co-primary endpoints met; 17.8kg absolute loss
A (topline)
LIVERAGE Phase 3 MASH
MASH + fibrosis F2-F3
Phase 3; 52wk + 7yr outcomes
Ongoing; results 2027-2028
Pending
LIVERAGE-Cirrhosis
Compensated MASH cirrhosis (F4)
Phase 3
Ongoing
Pending
SYNCHRONIZE-CVOT
Obesity + CVD risk
Long-term cardiovascular safety
Ongoing
Pending
Survodutide occupies a specific position in the obesity pharmacotherapy landscape — it is the first GLP-1/glucagon dual agonist to complete Phase 3 and the most important MASH pipeline compound. Understanding where it fits requires understanding what the glucagon component adds vs what GIP adds.
Feature
Tirzepatide (GLP-1+GIP)
Survodutide (GLP-1+GCGR)
Second receptor
GIP receptor (GIPR)
Glucagon receptor (GCGR)
Second receptor location
Pancreas, fat, bone, CNS
Liver (primary), fat, heart
Weight loss mechanism
GLP-1 appetite suppression + GIP adipose/CNS
GLP-1 appetite suppression + glucagon thermogenesis
Hepatic fat effect
Indirect (weight loss-mediated)
Direct + indirect (GCGR on hepatocytes + weight loss)
Phase 3 WL (obesity)
−22.5% (SURMOUNT-1, 72 weeks)
−16.6% (SYNCHRONIZE-1, 76 weeks — topline)
MASH efficacy
Phase 2 MASH (NEJM 2024, Loomba): 54% resolution vs 35% placebo; 12-week Phase 2
Phase 2 MASH (NEJM 2024, Sanyal): 62% resolution vs 14% placebo; 48-week Phase 2
MASH FDA status
No dedicated MASH indication
Breakthrough Therapy designation for MASH
GI tolerability
Nausea/vomiting (similar GLP-1 class profile)
Higher nausea (66% vs 44% for semaglutide) — glucagon adds GI stimulus
Approval status
FDA approved (T2D 2022; obesity 2023)
Not approved; SYNCHRONIZE-1 Phase 3 positive April 2026
Hyperglycemia risk
None (GIP enhances glucose-dependent insulin)
Managed by GLP-1 component; theoretical concern resolved by dual design
The head-to-head comparison for MASH is the critical clinical question: Phase 2 data for both compounds (published simultaneously in NEJM July 2024) shows survodutide at 62% resolution (48 weeks) vs tirzepatide at 54% resolution (52 weeks) — though populations, endpoints, and designs differ sufficiently that this is not a direct comparison. LIVERAGE Phase 3 vs tirzepatide's MASH program will eventually provide direct head-to-head context. For now, survodutide appears to be the more MASH-optimised compound by mechanism and by the available Phase 2 evidence.
For the community member currently making treatment decisions: if the primary concern is maximum weight loss — tirzepatide (approved) or CagriSema (NDA filed Q1 2026) are the leading options. If the primary concern is MASH — survodutide has the most compelling mechanism and the most compelling Phase 2 data, plus FDA Breakthrough Therapy designation, but it is not yet approved. The nearest-term option for someone with MASH today who wants a GLP-1 mechanism is semaglutide (the SELECT trial showed cardiovascular benefit in this population). Survodutide becomes the most relevant compound for MASH patients when Phase 3 LIVERAGE results arrive (2027-2028) and NDA submission follows.
The most important safety signal from the Phase 2 MASH trial: nausea 66% (vs 23% placebo), diarrhea 49% (vs 23%), vomiting 41% (vs 4%). These rates are higher than semaglutide's Phase 3 rates (nausea ~44%, vomiting ~24% in STEP 1) and appear to reflect the combined GLP-1 + glucagon receptor stimulation of GI tissue. The glucagon receptor is expressed in GI smooth muscle and the glucagon component may contribute additional GI adverse events beyond what the GLP-1 component alone would produce. Serious adverse events were not significantly different from placebo (8% vs 7%). The GI burden is concentrated during dose escalation — as with all GLP-1 class compounds, appropriate titration protocols are essential for tolerability. The Phase 3 SYNCHRONIZE program incorporates extended dose escalation schedules specifically to improve GI tolerability.
As a GLP-1 receptor agonist, survodutide carries the same class-level rodent medullary thyroid carcinoma (MTC) concern as semaglutide, tirzepatide, and all other GLP-1 agonists — driven by GLP-1R on thyroid C-cells in rodent models. The expected label will include MTC contraindications and MEN2 exclusion. Additionally, the GCGR component: glucagon receptors are also expressed on thyroid C-cells in some species. Whether GCGR activation adds to or is independent of the GLP-1R-mediated C-cell signal is not established in long-term human data. The regulatory expectation is that survodutide will carry at minimum the same MTC warning as other GLP-1 agents.
The theoretical concern with GCGR agonism in metabolic patients is hyperglycemia. In Phase 2, this concern was substantially addressed: survodutide showed no significant hypoglycemia or hyperglycemia in the Phase 2 trials — the GLP-1 component managed the glycemic balance effectively. In the obesity Phase 2 (non-diabetic population), the glycemic profile was clean. For the T2D MASH population (SYNCHRONIZE-2, LIVERAGE), glycemic monitoring will be more carefully characterized.
Survodutide and semaglutide share a GLP-1 receptor agonist component. They are pharmacologically distinct: survodutide adds glucagon receptor (GCGR) agonism that semaglutide completely lacks. The GCGR component drives direct hepatic fat oxidation (not present in semaglutide), increased thermogenesis (not present in semaglutide), and FGF21 induction. The Phase 2 MASH data showing 62% resolution at the optimal dose vs semaglutide's 59% in the NASH trial (different study, different population — not a direct comparison) suggests but does not prove superiority for liver disease. Survodutide is not a semaglutide copy.
This is the historical intuition that the survodutide program challenges. Glucagon receptor agonism in isolation causes hyperglycemia — this is correct. But in combination with GLP-1 receptor agonism, the GLP-1 component (glucose-dependent insulin secretion + glucagon suppression) manages the glycemic liability of GCGR activation. In Phase 2, survodutide showed no meaningful hyperglycemia signal in non-diabetic subjects. The glucagon component's hepatic fat-burning, thermogenic, and FGF21-inducing effects operate independently of the glycemic concern — they are properties of glucagon biology that the dual design captures while neutralizing the hyperglycemia.
Tirzepatide and survodutide address different mechanistic dimensions of the same metabolic disease cluster. Tirzepatide's GIP component provides additional weight loss and some MASH benefit. Survodutide's GCGR component provides direct hepatic fat oxidation that tirzepatide does not. For the MASH indication specifically — where liver disease is the primary target — survodutide has a more mechanistically direct action on the diseased tissue. Both compounds will likely have distinct patient populations for whom each is optimal. Phase 3 LIVERAGE will determine whether survodutide's MASH efficacy justifies its separate development alongside tirzepatide.
These figures are from different trials (SYNCHRONIZE-1 vs SURMOUNT-1), different populations, different durations, and different maximum doses. -16.6% in Phase 3 is clinically meaningful and is greater than semaglutide's Phase 3 -14.9%. Survodutide is not positioned primarily as a weight loss competitor to tirzepatide — its differentiated value proposition is in MASH, where the GCGR hepatic mechanism provides advantages that the weight loss comparison does not capture. A drug that resolves MASH in 62% of patients vs 14% placebo has enormous clinical value regardless of where its weight loss number sits relative to tirzepatide.
Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine. Published July 25, 2024. doi:10.1056/NEJMoa2401755. PMID 38847460. [The primary MASH evidence base; n=293; 48 weeks; MASH resolution 62% vs 14% placebo at 4.8mg; ≥30% liver fat reduction 67% vs 14%; fibrosis improvement 36% vs 22%; basis for FDA Breakthrough Therapy designation September 2024.]
Le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial. Lancet Diabetes and Endocrinology. 2024;12(3):162-173. PMID 38330987. [Phase 2b obesity; -18.7% WL at 46 weeks; 40% achieved ≥20% WL; established survodutide's obesity efficacy basis for Phase 3.]
Boehringer Ingelheim press release. April 29, 2026. SYNCHRONIZE-1 Phase 3 topline results: -16.6% body weight loss at 76 weeks vs -3.2% placebo; co-primary endpoints met; mean 17.8 kg absolute loss; full data ADA Scientific Sessions June 2026. [The most recent published survodutide data at time of writing — positive Phase 3 in obesity without T2D.]
Two Trials of Therapeutics for MASH with Liver Fibrosis (editorial). NEJM 2024. doi:10.1056/NEJMc2411003. [NEJM editorial comparing the simultaneous Phase 2 MASH publications for survodutide (Sanyal) and tirzepatide (Loomba) — establishes the head-to-head context for the two leading dual-agonist approaches to MASH.]
Survodutide is the most important obesity and MASH pipeline compound for anyone following the metabolic pharmacotherapy space. It is the most likely near-term competitor to both tirzepatide (for weight loss) and resmetirom (for MASH) — and the only compound in development with direct hepatic GCGR-mediated fat oxidation for MASH.
The honest summary: survodutide has a mechanistically compelling dual-receptor design, the most impressive Phase 2 MASH data in the field (62% resolution at 4.8mg vs 14% placebo in the NEJM), and just delivered positive Phase 3 obesity results (-16.6% at 76 weeks, SYNCHRONIZE-1, April 2026). The FDA has recognized its MASH potential with Breakthrough Therapy designation. Phase 3 LIVERAGE will be the definitive test — whether the 62% Phase 2 MASH resolution holds in a larger, more diverse Phase 3 population, and whether it translates to long-term liver disease prevention over 7 years. If it does, survodutide will likely become the first-choice pharmacotherapy for the enormous population with both obesity and MASH.
For community members: survodutide is not currently accessible as a research chemical and has minimal community use. Its inclusion in this book is forward-looking — for anyone with MASH or significant hepatic steatosis, survodutide is the most important compound to understand in the pipeline. If you currently have MASH and are on semaglutide or tirzepatide, you are accessing the GLP-1 mechanism that survodutide shares; the glucagon component's direct hepatic benefits await Phase 3 confirmation and eventual FDA approval. Watch for Phase 3 LIVERAGE results 2027-2028.
— End of Survodutide —
THE PEPTIDE BIBLE | Survodutide | For Research & Educational Purposes Only
Survodutide (BI 456906): dual GLP-1R + glucagon receptor (GCGR) agonist. Co-developed by Boehringer Ingelheim and Zealand Pharma. Once-weekly SubQ injection. Not FDA-approved as of May 2026. MECHANISM: GLP-1R component (appetite suppression; glucose-dependent insulin; gastric slowing; glucagon suppression) + GCGR component (direct hepatic fat oxidation; FGF21 induction; thermogenesis via brown adipose and sympathetic NS; lipolysis; hepatic lipogenesis suppression). The GCGR component manages the 'glucagon causes hyperglycemia' objection: GLP-1R's glucose-dependent insulin secretion counterbalances GCGR-driven glycogenolysis. PHASE 2 OBESITY (Lancet DE 2024; Le Roux et al.; PMID 38330987): -18.7% WL at 46 weeks; 40% achieved ≥20% WL; Phase 2b DBRCT. PHASE 2 MASH (NEJM July 25, 2024; Sanyal et al.; doi:10.1056/NEJMoa2401755): n=293; 48 weeks; MASH resolution without fibrosis worsening: 62% (4.8mg) vs 14% placebo (p<0.001 dose-response); ≥30% liver fat reduction: 67% vs 14%; fibrosis improvement ≥1 stage: 36% vs 22%; nausea 66% vs 23%; vomiting 41% vs 4%; serious AEs 8% vs 7%. PHASE 3 SYNCHRONIZE-1 (April 29, 2026 topline): obesity without T2D; 76 weeks; -16.6% WL vs -3.2% placebo (p<0.0001); 17.8 kg absolute; both co-primary endpoints met; full data ADA June 2026. FDA STATUS: Breakthrough Therapy designation for MASH (non-cirrhotic, F2-F3) September 2024. Fast Track Designation MASH 2021. PHASE 3 LIVERAGE: started October 2024; 52-week primary + 7-year outcomes. LIVERAGE-Cirrhosis (F4). SYNCHRONIZE-CVOT. SYNCHRONIZE-2 (obesity + T2D). APPROVAL TIMELINE: 2027 earliest. vs TIRZEPATIDE: tirzepatide = GLP-1+GIP; superior weight loss (-22.5% SURMOUNT-1); survodutide = GLP-1+GCGR; superior hepatic mechanism for MASH; Breakthrough Therapy for MASH (tirzepatide does not have this). SAFETY: GI AEs higher than semaglutide (66% nausea vs ~44%); MTC class concern applies (GLP-1R on C-cells); GCGR on C-cells — additional MTC consideration; glycemia managed by GLP-1 component. COMMUNITY STATUS: minimal research chemical access; forward-looking chapter for MASH patients. WADA: not listed.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.